All In Biotech

Drug Trial Radar · NCT04053634

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 689 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

689

Actual

Start

Aug 26, 2019

Primary completion

Jul 28, 2025

Study completion Jul 28, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL). Eligible patients must have a history of ≥2 moderate and/or severe COPD exacerbations in the previous year despite receiving triple (ICS/LABA/LAMA) background therapy for at least 3 months and ICS-based dual inhaled treatment for the remainder of the year. Eligible patients must also have an elevated blood eosinophil count. The treatment period will be of variable duration and will continue until the last patient has the opportunity to complete a minimum of 56 weeks, at which point all patients will complete the study. The primary endpoint will be analyzed at Week 56.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • BenralizumabBiological

    Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

  • PlaceboBiological

    Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=3 Exacerbations in the Previous Year.Time frame: up to Week 56
  2. Annualized Rate of Moderate or Severe COPD Exacerbations of Participants With >=2 Exacerbations in the Previous YearTime frame: up to Week 56

Locations

342 sites in 30 countries. Site status is shown where the registry gives one.

  • Research Site

    Surprise, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Palm Springs, California

  • Research Site

    Westminster, California

  • Research Site

    Stamford, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    Edgewater, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Leesburg, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Pensacola, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Lawrenceville, Georgia

  • Research Site

    Rincon, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    O'Fallon, Illinois

  • Research Site

    Peoria, Illinois

  • Research Site

    Michigan City, Indiana

  • Research Site

    Iowa City, Iowa

  • Research Site

    Kansas City, Kansas

  • Research Site

    Georgetown, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Columbia, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    North Dartmouth, Massachusetts

  • Research Site

    Farmington Hills, Michigan

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Omaha, Nebraska

  • Research Site

    Toms River, New Jersey

Showing 40 of 342 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.